S C Danhauer1, G A Brenes2, B J Levine1, L Young3, H A Tindle4, E L Addington5, R B Wallace6, M J Naughton7, L Garcia8, M Safford9, M M Kim10, E S LeBlanc11, B M Snively12, L G Snetselaar6, S Shumaker1. 1. Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston Salem, NC. 2. Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston Salem, NC. 3. Department of Medicine, Division of Endocrinology and Metabolism, Section on Gerontology and Geriatric Medicine, UNC School of Medicine, Chapel Hill, NC. 4. Division of General Internal Medicine and Public Health, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. 5. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL. 6. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA. 7. Division of Cancer Prevention and Control, Department of Internal Medicine, The Ohio State University, Columbus, OH. 8. Department of Public Health Sciences, University of California Davis School of Medicine, Davis, CA. 9. Department of Medicine, Weill Cornell Medical College, New York, NY. 10. Center for Biobehavioral Health Disparities Research, Department of Community and Family Medicine, Duke University, Durham, NC. 11. Kaiser Permanente Center for Health Research NW, Portland, OR, USA. 12. Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, WinstonSalem, NC, USA.
Abstract
AIMS: To examine (1) the prevalence of depressive symptoms in women with Type 2 diabetes, (2) the associations between depressive symptoms and the following dependent variables: sleep disturbance; physical activity; physical health-related; and global quality of life, and (3) the potential moderating effects of antidepressants and optimism on the relationship between depressive symptoms and dependent variables. METHODS: Participants in the Women's Health Initiative who had Type 2 diabetes and data on depressive symptoms (N=8895) were included in the analyses. In multivariable linear regression models controlling for sociodemographic, medical and psychosocial covariates, we examined the main effect of depressive symptoms, as well as the interactions between depressive symptoms and antidepressant use, and between depressive symptoms and optimism, on sleep disturbance, physical activity, physical health-related quality of life; and global quality of life. RESULTS: In all, 16% of women with Type 2 diabetes reported elevated depressive symptoms. In multivariable analyses, women with depressive symptoms had greater sleep disturbance (P<0.0001) and lower global quality of life (P<.0001). We found evidence of significant statistical interaction in the models for quality-of-life outcomes: the increased risk of poor physical health-related quality of life associated with antidepressant use was stronger in women without vs with depressive symptoms, and the association between greater optimism and higher global quality of life was stronger in women with vs without depressive symptoms. CONCLUSIONS: To improve health behaviours and quality of life in women with Type 2 diabetes, sociodemographic and medical characteristics may identify at-risk populations, while psychosocial factors including depression and optimism may be important targets for non-pharmacological intervention.
AIMS: To examine (1) the prevalence of depressive symptoms in women with Type 2 diabetes, (2) the associations between depressive symptoms and the following dependent variables: sleep disturbance; physical activity; physical health-related; and global quality of life, and (3) the potential moderating effects of antidepressants and optimism on the relationship between depressive symptoms and dependent variables. METHODS:Participants in the Women's Health Initiative who had Type 2 diabetes and data on depressive symptoms (N=8895) were included in the analyses. In multivariable linear regression models controlling for sociodemographic, medical and psychosocial covariates, we examined the main effect of depressive symptoms, as well as the interactions between depressive symptoms and antidepressant use, and between depressive symptoms and optimism, on sleep disturbance, physical activity, physical health-related quality of life; and global quality of life. RESULTS: In all, 16% of women with Type 2 diabetes reported elevated depressive symptoms. In multivariable analyses, women with depressive symptoms had greater sleep disturbance (P<0.0001) and lower global quality of life (P<.0001). We found evidence of significant statistical interaction in the models for quality-of-life outcomes: the increased risk of poor physical health-related quality of life associated with antidepressant use was stronger in women without vs with depressive symptoms, and the association between greater optimism and higher global quality of life was stronger in women with vs without depressive symptoms. CONCLUSIONS: To improve health behaviours and quality of life in women with Type 2 diabetes, sociodemographic and medical characteristics may identify at-risk populations, while psychosocial factors including depression and optimism may be important targets for non-pharmacological intervention.
Authors: Hilary Tindle; Bea Herbeck Belnap; Patricia R Houck; Sati Mazumdar; Michael F Scheier; Karen A Matthews; Fanyin He; Bruce L Rollman Journal: Psychosom Med Date: 2012-01-27 Impact factor: 4.312
Authors: Hilary A Tindle; Yue-Fang Chang; Lewis H Kuller; JoAnn E Manson; Jennifer G Robinson; Milagros C Rosal; Greg J Siegle; Karen A Matthews Journal: Circulation Date: 2009-08-10 Impact factor: 29.690
Authors: Christopher M Celano; Eleanor E Beale; Shannon V Moore; Deborah J Wexler; Jeff C Huffman Journal: Curr Diab Rep Date: 2013-12 Impact factor: 4.810
Authors: Jayati Das-Munshi; Rob Stewart; Khalida Ismail; Paul E Bebbington; Rachel Jenkins; Martin J Prince Journal: Psychosom Med Date: 2007-07-16 Impact factor: 4.312
Authors: Karen L Margolis; Robert Brzyski; Denise E Bonds; Barbara V Howard; Sarah Kempainen; Jennifer G Robinson; Monika M Safford; Lesley T Tinker; Lawrence S Phillips Journal: Clin Trials Date: 2008 Impact factor: 2.486